Skip to main content

Table 6 The most significant genetic predictors of drug response

From: Animal models and conserved processes

Organ or system involved Associated gene/allele Drug/drug response phenotype
Red blood cells G6PD Primaquine and others
Neutrophils TMPT*2 Azathioprine/6MP-induced neutropenia
  UGT1A1*28 Irintotecan-induced neutropenia
Plates CYP2C19*2 Stent thrombusis
Coagulation CY2C9*2, *3, VKORC1 Warfarin dose-requirement
Brain and peripheral nervous system
CNS depression CYP2D6*N Codeine-related sedation and respiratory depression
Anaesthesia Butyrylcholinesterase Prolonged apnoea
Peripheral nerves NAT-2 Isoniazid-induced peripheral neuropathy
Drug hypersesitivity HLA-B*5701 Abacavir hypersensitivity
  HLA-B*1502 Carbamazepine-induced Steve Johnson syndrome (in some Asian groups )
  HLA-A*3101 Carbamazepine-induced hypersensitivity in Causians and Japanese
  HLA-B*5801 Allopurinol-induced serious cutaneous reactions
Drug-induced liver injury HLA-B*5701 Flucloxacillin
  HLA-DR81*1501-DQ81*0602 Co-amoxiclav
  HLA-DR81*1501-DQ81*0602 Lumiracoxib
  HLA-BR81*07-DOA1*02 Ximelagatran
  HLA-DQA1*0201 Lapatinib
HIV-1 infection CCRS Maraviroc efficacy
Hepatitis C infection IL288 Interferon-alpha efficacy
Breast cancer CYP2D^ Response to tamoxifen
Chronic myeloid leukaemia BCR-ABL Imatinib and other tyrosine kinase inhibitors
Colon cancer KRAS Cetuximab efficacy
GI stromal tumours c-kit Imatinib efficacy
Lung cancer EGFR Gefinib efficacy
  EML4-ALK Crizotinib efficacy
Malignant melanoma BRAF V600E Vemurafenib efficacy